Max Bittrich

539 citations
20 papers · 243 indexed · h-index 9
Topics
Multiple Myeloma Research and Treatments (14 papers)Protein Degradation and Inhibitors (7 papers)Cancer Treatment and Pharmacology (2 papers)
Partner nations
GermanyItalySpain

In The Last Decade

Max Bittrich

20 papers receiving 238 citations

Peers

Max Bittrich
Comparison fields: 5 of 47
  • Oncology 130
  • Hematology 109
  • Molecular Biology 101
  • Immunology 57
  • Pulmonary and Respiratory Medicine 39
Replace Hamdi Sati with:
Hamdi Sati United Kingdom
Manfred Ahlgrimm Germany
Mahan Moshir Belgium
Michela Boi Switzerland
Taku Tsukamoto Japan
Tarik Kanouni France
Corina Schneidawind Germany
Ramya Muddasani United States
Elena Agape Italy
Mary McCauley United States
Max Bittrich relative to Hamdi Sati United Kingdom Hamdi Sati's profile →
Citations per field
00.5×10×15×22×
Hamdi Sati · 1×
Citations per year

Countries citing papers authored by Max Bittrich

Since Specialization
Citations

This map shows the geographic impact of Max Bittrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Bittrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Bittrich more than expected).

Fields of papers citing papers by Max Bittrich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Bittrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Bittrich. The network helps show where Max Bittrich may publish in the future.

Co-authorship network of co-authors of Max Bittrich

This figure shows the co-authorship network connecting the top 25 collaborators of Max Bittrich. A scholar is included among the top collaborators of Max Bittrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Bittrich. Max Bittrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 3
2 6
3 7
4 3
5 3
6 8
7 10
8 30
9 10
10 20
11 14
12 8
13 6
14 14
15 10
16 1
17 2
18 2
19 53
20 33

About Max Bittrich

Max Bittrich is a scholar working on Hematology, Oncology and Immunology and Allergy, having authored 20 papers that have together received 243 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (14 papers), Protein Degradation and Inhibitors (7 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Hematology (109 citations), Oncology (130 citations) and Immunology (57 citations). Max Bittrich has collaborated with scholars based in Germany, Italy and Spain. Frequent co-authors include Hermann Einsele, Antonio Giovanni Solimando, Andreas Rosenwald, Markus Krebs, Andreas Beilhack, Stefan Knop, K. Martin Kortüm, Martina Rudelius, Miriam Ritz and Regina Ebert. Their work appears in journals such as Journal of Clinical Oncology, Blood and International Journal of Molecular Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026